<DOC>
	<DOCNO>NCT02033668</DOCNO>
	<brief_summary>This study intend enable possible transition intramuscular ( IM ) subcutaneous ( SQ ) administration subsequent study GSK933776 characterize safety , tolerability , PK pharmacodynamic profile , immunogenicity GSK933776 follow IM SQ administration healthy volunteer . Such alternate route administration may provide option selection efficacious dose subsequent development patient geographic atrophy . There four treatment arm study participant assign 1 4 possible treatment arm 1:1:1:1 ratio . The planned number evaluable participant study 24 6 participant complete critical assessment four treatment arm . The total duration participation screen follow-up Treatment Arms A , B D ( single dose GSK933776 ) , approximately 113 day total duration Treatment Arm C ( repeat dose GSK933776 ) approximately 134 day .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Study GSK933776 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Male female subject 18 50 year age time sign informed consent In general good health determine physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree condition unlikely introduce additional risk factor interfere study procedure Body weight &gt; =55 kilogram ( kg ) ( 121 pound [ lbs ] ) &lt; =85 kg ( 187 lb ) body mass index ( BMI ) 18.5 29 kg per meter square ( inclusively ) time sign informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit ( MIU ) /milliliter ( mL ) estradiol &lt; 40 picogram/mL ( &lt; 140 picomoles/Liter ) confirmatory . Male subject must agree use one form acceptable contraception method partner childbearing potential . This criterion must follow time screen visit follow visit ( 84 day last dose study medication ) . Capable give write informed consent , include compliance requirement restriction list consent form . Known risk history Central nervous system ( CNS ) disorder : History and/or evidence ( compute tomography magnetic resonance imaging scan perform within past 12 month ) cerebral haemorrhage OR know risk cerebral haemorrhage , include uncontrolled hypertension , cerebrovascular malformation , coagulopathy , central nervous system ( CNS ) vasculitis , degenerative inflammatory/demyelinating CNS condition condition Investigator and/or medical monitor considers relevant risk factor cerebral haemorrhage . Transient ischemic attack ( TIA ) /cerebrovascular accident ( CVA ) last year , uncontrolled risk factor stroke ; History seizure ( except febrile seizure childhood ) recent unprovoked seizure ; Uncontrolled type 2 diabetes mellitus ( glycated hemoglobin &gt; 10 % ) , active cardiovascular disease ( e.g. , moderatesevere angina , unstable angina , myocardial infarction ( MI ) within last 2 year , symptomatic congestive heart failure , clinically significant arrhythmia ) ; Current blood clot bleed disorder condition predispose ( e.g . cancer ) ; Diagnosis currently active , , remission chronic relapsing , systemic autoimmune disease condition ( e.g . multiple sclerosis , lupus erythematosus etc ) Investigator and/or medical monitor considers relevant risk factor concomitant administration therapeutic monoclonal antibody . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Use prescription drug nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . A positive prestudy drug/alcohol screen . Current recent drug alcohol abuse dependence . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 unit male &gt; 7 unit female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Use illegal drug . History sensitivity study medication , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . Seated systolic blood pressure &gt; 140 millimeter mercury ( mmHg ) seat diastolic blood pressure &gt; 90 mmHg QTc &gt; 450 millisecond ( msec ) . Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &gt; = 2xupper limit normal ( ULN ) ; alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Significant abnormality hematology screen : clinically significant anemia ( i.e . hemoglobin &lt; 11 g/deciliter [ dL ] male &lt; 10 g/dL female ) , platelet count 124 Giga/L ; International Normalized Ratio &gt; 2 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test human immunodeficiency virus antibody Where participation study would result donation blood blood product excess 500 mL within 56 day period . Exposure four new chemical entity within 12 month prior screen . Prior allergic reaction biological product ( vaccine , antibody ) know hypersensitivity component drug formulation . Prior participation clinical investigation involve therapeutic monoclonal antibody similar mode action proteins derive monoclonal antibody risk cross reactivity investigation treatment use investigational medication device within 2 month prior screen within 5 halflives use medication prior screening , whichever longer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>intravenous</keyword>
	<keyword>subcutaneous intramuscular administration</keyword>
	<keyword>amyloid beta</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>